HighTide Therapeutics, Inc.

中 | ENG
  • About Us
    • Leadership
    • Contact
  • Our Focus
    • Overview
    • T2DM
    • MASH
    • Obesity
    • PSC
  • Science
    • Pipeline
    • HTD1801
    • Discovery Portfolio
    • Scientific Publications
    • Expanded Access Policy
  • News
  • Investors
  • Culture & Careers
    • Culture
    • Open Positions

News

HighTide Therapeutics invited to present at the World Orphan Drug Congress USA 2019

Jeffrey Dao, Operations & Business Development Officer to present HighTide’s HTD1801 for primary sclerosing cholangitis (PSC) at the World Orphan Drug Congress USA 2019 in Oxon Hill, MD

©2025 HighTide Therapeutics, Inc.

  • Terms of Use
  • Privacy Policy
MENU
  • About Us
    • Leadership
    • Contact
  • Our Focus
    • Overview
    • T2DM
    • MASH
    • Obesity
    • PSC
  • Science
    • Pipeline
    • HTD1801
    • Discovery Portfolio
    • Scientific Publications
    • Expanded Access Policy
  • News
  • Investors
  • Culture & Careers
    • Culture
    • Open Positions